Skip to main content
. 2026 Sep 16;18(18):3007. doi: 10.3390/cancers18183007
ADT Androgen Deprivation Therapy
CBR Clinical Benefit Rate
CI Confidence Interval
EHR Electronic Health Record
IPF Iterative Proportional Fitting
mHSPC Metastatic Hormone-Sensitive Prostate Cancer
ORR Objective Response Rate
OS Overall Survival
PFS Progression-free Survival
PSA Prostate-specific Antigen